Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Chemistry World January 11, 2013 Andrew Turley	Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger.
Chemistry World October 26, 2011 Maria Burke	Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Chemistry World July 16, 2012 Andrew Turley	Drug spending to hit $1.2tn in 2016 Global expenditure on medicines will top $1.2 trillion in 2016, up from $960 billion in 2011, according to a report from the IMS Institute for Healthcare Informatics.
Pharmaceutical Executive September 1, 2012 Thomas Baker	The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support.
BusinessWeek April 15, 2010 Kanoko Matsuyama	Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
Registered Rep. May 10, 2012 Jennifer Duell Popovec	Emerging Real Estate in Emerging Markets While most investors lack a deep understanding of emerging markets overall, most of them know enough to be excited about these countries and the investment opportunities they offer.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Pharmaceutical Executive March 1, 2013	China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Chemistry World December 23, 2009 Sean Milmo	2009 marks the start of the great divide The recession is opening up a big gap in output performance between the chemical industries of the developed and developing worlds, which will continue to widen over the next few years.
Pharmaceutical Executive May 1, 2012	Government: Big Pharma's Best Friend in Emerging Markets? To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.
Pharmaceutical Executive February 1, 2013 Julian Upton	Turkey: A Promise Restored? After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase.
Pharmaceutical Executive December 1, 2010 Chaturvedi & French	US Anti-Corruption Regulation Risks Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
On Wall Street January 1, 2013	Five Questions with DoubleLine Funds' Luz Padilla Luz Padilla, the senior portfolio manager at DoubleLine Funds discusses emerging markets and opportunities for global investing.
Finance & Development June 2011	Emerging Challenges Emerging markets must adapt to the new global reality by building on their economic success.
BusinessWeek June 25, 2007 Catherine Arnst	IMS Health: Where The Best Medicine Is Data Drugmakers have come to rely on the company's inside track on the prescriptions doctors write.
Pharmaceutical Executive October 1, 2012	Country Report: Turkey In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. The pharmaceutical industry has also enjoyed a wave of expansion.
Chemistry World February 15, 2008 James Mitchell Crow	Industry Reports a Year of Mixed Fortune Despite the twin pressures of rising energy and feedstock prices, and a slowing economy in the US curbing demand, many companies in the chemical sectors have reported rising sales and profits in their financial reviews of 2007.
The Motley Fool April 13, 2009 Anand Chokkavelu	Why India Is No China When it comes to international investing, it's convention to lump countries into one of two categories: developed markets vs. emerging markets. But apart from scale and high portfolio inflows India and China don't share that much in common.
The Motley Fool December 8, 2011 John Grgurich	What You Need to Know About Brazil's Slowing Economy Here's what's happening with emerging market Brazil, and how it could affect you.
Finance & Development December 2010	Emerging Markets Come of Age These vibrant middle-income countries survived the global recession, but face bumps as they seek to solidify their place in the world economy.
Finance & Development June 1, 2000 Mohamed A. El-Erian	Where Are Emerging Markets Headed? The emerging markets look very different in early 2000. Growth is picking up in most economies, with countries like Brazil also making remarkable financial recoveries and Mexico just being upgraded by Moody's to the much-coveted investment rating.
Finance & Development March 2011 Clements et al.	Healing Health Care Finances Health care presents a daunting fiscal challenge in advanced and emerging economies alike, but reforms can help manage the growth of spending fairly and efficiently.
Investment Advisor June 1, 2011 Jim McAllister	Emerging and Developed Markets -- Decoupling or a Reversion to the Mean? Vast differences in economic growth rates are at work in the performance disparity between developed and emerging markets.
The Motley Fool June 11, 2010	Is There an Emerging Markets Bubble? Speaking this week at his employer's Franklin Templeton Emerging Markets Conference, Dr. Mark Mobius, the sector expert and executive chairman of Templeton Asset Management, aimed to deflate talk of an emerging market bubble.
Chemistry World September 19, 2011 Maria Burke	Higher education funding rises around the world 'While our universities are experiencing cuts, other nations are pumping billions more into their universities to gain a competitive edge,' says Wendy Piatt, director-general of the Russell Group, which represents 20 research intensive UK universities.
The Motley Fool September 5, 2006 Will Frankenhoff	You Can't Afford Not To People often talk about the risks involved with investing in emerging markets. But given the current trends, can you really afford not to have at least some exposure to emerging market equities?
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Chemistry World February 2, 2010 Ned Stafford	Russian science losing its edge Research in Russia, considered a scientific powerhouse during the cold war years, has faded in global importance since the break-up of the former Soviet Union in the early 1990s and now is lagging behind China and India.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Finance & Development December 2011 Eswar S. Prasad	Role Reversal Emerging economies are less dependent on debt, less vulnerable to volatile investment sentiment, and are rethinking the role of capital flows
The Motley Fool January 18, 2007 Bill Mann	The Coming Emerging Markets Disaster Just like with tech stocks circa 1999, is the hard landing coming for emerging market stocks because we're no longer considering risk?
The Motley Fool October 11, 2011 Cliff D'Arcy	AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China.
Chemistry World March 16, 2007	Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London.
Chemistry World February 2012	Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment.
Pharmaceutical Executive August 1, 2011 William Looney	Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders
Chemistry World November 16, 2009 Hepeng Jia	Chinese NASDAQ brings little to chemicals industry Similar to the US NASDAQ, most of the listed firms in the Chinese GEM are technology-oriented companies. Classified by industry, electronics and pharmaceutical manufacturers are the biggest groups
The Motley Fool December 27, 2011 Dan Caplinger	Why Emerging Markets Fell Apart in 2011 Will hot countries come back next year?
Pharmaceutical Executive February 1, 2011 William Looney	Tracking the US Market: A Statistical Self-Portrait What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
Pharmaceutical Executive February 1, 2009 Patrick Clinton	Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people.
Investment Advisor June 2006	S&P Mutual Fund Sector Focus: Emerging Market Debt Rises Bonds issued by emerging markets countries have benefited from an improving balance of payments, as well as trade and current account surpluses since increased global demand for products from these nations particularly commodities, have boosted their exports and reduced debt.
AskMen.com Stephen Pym	Emerging Markets Crash Just like Americans returning from winter vacations, American dollars are also flying back to the U.S. from warmer climes right now -- which could be bad news for emerging markets.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
On Wall Street August 1, 2013 Lorie Konish	Selling U.S. Investors on Emerging Markets Compared to their foreign peers, U.S. investors are skittish on emerging markets. Here s why some think they re missing the boat.